BCC
KRYS icon

Bridge City Capital’s Krystal Biotech KRYS Stock Holding History

Bridge City Capital’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.39M Sell
11,816
-229
-2% -$68.4K 1% 35
2026
Q1 		$3.11M Sell
12,045
-90
-0.7% -$23.9K 0.86% 44
2025
Q4 		$2.99M Sell
12,135
-2,019
-14% -$425K 0.88% 49
2025
Q3 		$2.5M Buy
+14,154
New +$2.12M 0.67% 69

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bridge City Capital's KRYS Position: Q2 2026 in Review

Bridge City Capital reduced its Krystal Biotech (KRYS) stake by 1.9% in Q2 2026, selling an estimated $68.4K and leaving 11,816 shares worth $4.39M. The position accounts for 1% of the portfolio, ranked #35.

Bridge City Capital first reported a position in KRYS in Q3 2025 and has held it in 4 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Bridge City Capital held 11,816 shares of Krystal Biotech worth $4.39M as of Q2 2026.
  • Bridge City Capital sold 229 Krystal Biotech shares in Q2 2026, an estimated $68.4K.
  • Krystal Biotech made up 1% of Bridge City Capital's portfolio in Q2 2026, its #35 holding.
  • Bridge City Capital first reported a position in Krystal Biotech in Q3 2025 and has held it in 4 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Bridge City Capital's 13F filing for Q2 2026, filed 11 Aug 2026.